Janus Kinase Inhibitor as a Therapeutic Option in Alopecia Areata: Case Report

August 2021 in “ Revista Colombiana de Reumatología/Revista Colombiana de Reumatologia ”

Lina María Saldarriaga Rivera, Christian David Marín Giraldo, Fabián Andrés Hernández Velasco

alopecia areata autoimmune condition non-scarring hair loss tofacitinib Janus kinase inhibitor biopsy AA JAK inhibitor

TLDR Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.

This case report discusses a 24-year-old female patient with alopecia areata (AA) who experienced extensive hair loss over four years, unresponsive to various treatments including minoxidil, clobetasol, oral and intralesional corticosteroids, finasteride, and cryotherapy. The study highlights the significant emotional and social impact of AA and the challenges in managing resistant cases. It presents the first reported successful use of the JAK inhibitor tofacitinib in a patient with AA in Colombia, suggesting its potential as an effective treatment option for difficult-to-control AA. Ethical considerations were adhered to, with informed consent obtained, and no conflicts of interest or funding were reported.

View this study on sciencedirect.com →

Discuss this study in the Community →

Research cited in this study

11 / 11 results

research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis

130 citations, February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

130 citations, February 2018 in “Journal of Investigative Dermatology”

Tofacitinib may help treat severe hair loss, but more research is needed.

research Alopecia Areata: Treatment Options and Efficacy

182 citations, December 2017 in “Journal of the American Academy of Dermatology”

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

research JAK Inhibitors in Dermatology: The Promise of a New Drug Class

355 citations, January 2017 in “Journal of the American Academy of Dermatology”

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations, November 2016 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations, September 2016 in “JCI insight”

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

research Health-Related Quality of Life Among Patients With Alopecia Areata: A Systematic Review

95 citations, July 2016 in “Journal of The American Academy of Dermatology”

People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.

research Alopecia Areata and Health-Related Quality of Life: A Systematic Review and Meta-Analysis

128 citations, February 2016 in “British Journal of Dermatology”

Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations, August 2014 in “Nature medicine”

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

185 citations, June 2014 in “Journal of Investigative Dermatology”

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

research British Association of Dermatologists’ Guidelines for the Management of Alopecia Areata 2012

218 citations, April 2012 in “British Journal of Dermatology”

Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.

Related Community Posts Join

6 / 1000+ results

community Diffuse hair loss and scalp biopsies

in Research 692 upvotes 4 months ago

Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

community TE turned into Scarring hairloss

in Update 12 upvotes 9 months ago

The user experienced hair loss due to a crash diet and later developed scarring hair loss. They are now on finasteride, oral minoxidil, LDN, Zyrtec, and Oztela to reduce scalp inflammation and promote hair regrowth.

community The Worst Hair Loss Condition You (MAY) have: LPP

in Research/Science 43 upvotes 3 months ago

Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

community scarring alopecia awareness in this community

in Chat 33 upvotes 2 years ago

Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.

community Topical Anti-Androgen users. What are y’all using currently? And what do you believe has the best chance of being approved? Or best results?

in Technology 13 upvotes 2 months ago

RU58841 is considered effective by some users, but finasteride and minoxidil are commonly used with varying dosages to manage side effects. Users report different experiences with treatments like pyrilutamide, fluridil, and RU58841, with some seeing results and others not.

community C’est terrible - at my wits end

in Female 443 upvotes 1 year ago

A 29-year-old woman is experiencing gradual hair thinning since age 15, suspects Androgenic Alopecia, and has tried 5% minoxidil with little success. She has purchased various hair loss treatments including minoxidil, dutasteride, finasteride, and spironolactone, but is cautious about starting them due to potential interactions with her ADHD medication.

Related Research

4 / 4 results

research Alopecia Areata: A Multifactorial Autoimmune Condition

148 citations, December 2018 in “Journal of autoimmunity”

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

research Linear Alopecia Areata

4 citations, November 2018 in “JAAD case reports”

Alopecia areata can sometimes appear as a straight line of hair loss instead of round patches.

research Treating Resistant Cases of Alopecia Universalis

May 2018 in “Journal of cosmetology & trichology”

Combining platelet-rich plasma therapy with prostaglandin-F eye drops can significantly regrow hair in alopecia universalis.

research Overview of Alopecia Areata

110 citations, December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings”

Alopecia areata is a genetic and immune-related hair loss condition that is often associated with other autoimmune diseases and does not typically cause permanent damage to hair follicles.